23andMe

The truth about global health

Monday, August 17, 2015

The Pulse on Global Trials by Matthew Howes

How you see the world depends on where you are. From one side of a room, the shadow of a cylinder may appear as a square; from the other side, a circle. Each perspective is true to the observer, but the truth is that both are correct.

[Read More]

23andMe launches Lupus research study in collaboration with Pfizer

Thursday, May 14, 2015

23andMe, a personal genetics company based in Mountain View, Calif., has launched the Lupus Research Study in collaboration with Pfizer. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort also is in collaboration with the Lupus Research Institute and in concert with Lupus Awareness Month in May.

[Read More]

23andMe, Genentech partner to analyze genomic data for Parkinson’s

Thursday, January 8, 2015

23andMe, a privately held personal genomics and biotechnology company based in Mountain View, Calif., has inked an agreement with Genentech, a member of the Roche Group, to generate whole genome sequencing data for approximately 3,000 people in 23andMe’s Parkinson’s disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson’s disease.

[Read More]

23andMe launches national TV campaign

Friday, August 9, 2013

23andMe, a personal genetics company, has launched Portraits of Health, the company’s first television advertising campaign. The campaign focuses on educating consumers about how understanding their DNA can help them make more informed and proactive health decisions.

[Read More]

23andMe raises more than $50M in new financing

Monday, December 17, 2012

23andMe, a personal genetics company based in Mountain View, Calif., has raised more than $50 million in a Series D financing. Participants in the financing include Yuri Milner, a new investor, as well as existing investors Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. This investment will help the company achieve its growth goal of one million customers.

[Read More]